Background Cognitive decline is a common presentation of Parkinson’s disease (PD) and a continued search exists for a reliable biomarker for early identification and management of this clinical problem. The objective of this study is to select the most useful biomarker in assessment of PD-related cognitive decline. This cross-sectional study included 47 patients with PD and 47 matched healthy controls. All participants were assessed by quantitative electroencephalography (QEEG) spectral (relative power and background peak frequency) and connectivity measures (coherence and phase lag degree), in addition to clinical evaluation using Unified Parkinson’s Disease Rating Scale (UPDRS)and Modified Hoehn and Yahr staging scale and neuropsychological assessment of the patients using Montreal Cognitive Assessment (MoCA). Results PD patients showed significantly higher relative power in all frequency bands over the right temporal region with no significant changes in peak frequency, coherence and phase lag degree compared to healthy controls. PD patients with impaired cognition (MoCA < 26) had significantly lower global relative power, more marked in alpha and beta frequency bands compared to PD patients with normal cognition. Alpha and beta relative power in frontal and temporal regions showed significant correlation with different cognitive domains of MoCA score. Conclusions QEEG measures especially spectral relative power could be used as adjunct to neuropsychological assessment in evaluation of PD-related cognitive decline.
ـــــــ ــــــــ ــــــــ ــــــــــــــــــــــــــــــــــــ ـ ـــــــــــــــــــــــــــــــــــــــــــــــــــ Background and Aim: Neuroinflammation plays an early and prominent role in the pathology of Parkinson disease. Tumor necrosis factor alpha induced protein-8 like-2 (TIPE2) is a relatively new subtype of tumor necrosis factor which may play a role in pathogenesis of Parkinson disease. Our aim was to evaluate the role of serum level of TIPE2 as a risk factor for Parkinson disease and as a serological biomarker of disease severity. Methods: Forty-seven patients diagnosed as idiopathic PD according to diagnostic criteria of the UK Parkinson Disease Society Brain Bank, and 47 healthy individuals were enrolled. All patients were on medical treatment of PD and were evaluated by Unified
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.